I
schemic tissue injury plays a crucial role in cardiovascular medicine. 1 In addition to ischemia, reperfusion itself can result in increased damage to ischemic tissue (ischemia-reperfusion [IR] injury). 2, 3 First, free oxygen radicals damage cellular proteins and membranes and may ultimately lead to mitochondrial disruption. 4 In a second step, neutrophil activation and invasion are driving the deleterious cascade of IR injury. 5 Several strategies have been demonstrated to prevent IR injury in various experimental settings. [6] [7] [8] [9] [10] However, transfer of in vitro or animal experience to the clinical stage is challenging. The timely reperfusion remains the main approach to avoid sustained tissue damage. 11 We previously evaluated the protective effect of ischemic preconditioning in healthy human subjects. 12 However, the transfer towards the clinical area is limited by the access to tissue at risk, especially for the human heart. This led to the intensive evaluation of the more practical remote ischemic preconditioning, which, however, did not prove clinical effectiveness.
IR injury may be attenuated by pharmacological HO-1 induction with heme arginate. [18] [19] [20] [21] [22] The effect can be compared with ischemic preconditioning. 23 Previous data have confirmed dose-dependent induction of HO-1 mRNA and protein by heme arginate in venous blood of healthy subjects. 24, 25 Further, we established a human in vivo model supporting the hypothesis of the protection induced by heme arginate in healthy human skeletal muscle after IR injury. 26 We previously identified a potential role of the HO-1 promoter region polymorphism for the development of graft vasculopathy after cardiac transplantation. 27 Finally, we designed this trial to provide clinical evidence for HO-1 induction in the human heart. HO-1 mediated protection may be specifically beneficial in this setting. First, ischemic heart disease represents still one of the leading causes of death in the industrialist world. 1, 28 An improved protection from ischemia may be beneficial in any kind of acute coronary syndromes regardless of the planned revascularization strategy. In addition, several procedures in cardiac surgery, including transplantation necessitate some degree of myocardial ischemia, which may lead to adverse events. Within this clinical trial, we studied if HO-1 is induced in the human heart after a single intravenous infusion of heme arginate administered 24 hours before elective cardiac surgery.
Materials and Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Clinical Trial Design
A placebo-controlled, randomized, double-blinded study design with 2 treatment groups and 1 placebo group was conducted in patients undergoing aortic valve replacement.
The trial was approved by the Ethics Committee of the Medical University of Vienna (EK No.: 1211/2013) and is registered at EudraCT (2013-000887-27). A sample size of 24 patients was calculated according to our previous trial. 26 The ethical board approved up to 36 patients with an interim analysis of the first 24 patients. Eligible patients were included between March 2015 and June 2017 after written informed consent was obtained. Inclusion criteria were age between 40 and 85 years and a body mass index <35 kg/m 2 . Any of the following criteria excluded a patient from study participation: known hypersensitivity to the study drug, treatment with another investigational drug within 3 weeks before screening, history or clinical evidence of any disease, and existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study drug, severe renal failure (glomerular filtration rate <30 mL/min), moderately or severely impaired left or right ventricular function (ejection fraction <40%), systolic pulmonary pressure >45 mm Hg, acute or recent (<7 days) myocardial infarction, and childbearing potential.
Screening, randomization, and drug administration were performed after hospitalization at the Medical University of Vienna. Patients were randomized to the study groups by the randomizer program with equally sized blocks for 24 and 36 patients according to the study protocol (Medical University Graz, Graz, Austria). Surgery was scheduled 24 hours after study drug administration according to our previous trial, which indicated the strongest effect of protein induction in peripheral blood mononuclear cells (PBMCs) after 24 hours. 25 One of the following treatments were administered as a single intravenous infusion: heme arginate at a dose of 1 mg/kg or 3 mg/kg (NORMOSANG, Orphan Europe Ltd, Paris, France) diluted to 110 mL with 0.9 % sodium chloride, or an equivalent volume of 0.9% sodium chloride solution as placebo. To avoid any local irritation from drug infusion, 250 mL 0.9% sodium chloride solution was administered thereafter. A nontransparent infusion kit was used to maintain the blind. Full sternotomy and cold blood cardioplegia (antegrade and retrograde) were used in every case. A small biopsy (1-2 mm) was taken from the right ventricular free wall with a liver biopsy needle directly before cross-clamping and after clamp release before weaning from cardiopulmonary bypass. Furthermore, the right atrial appendage was clamped and cut for cannulation before cardiopulmonary bypass, and this sample was also send for analysis. All tissue samples were snap-frozen in the operating theater directly after sampling. The surgical team was blinded about the study group to avoid any bias during sampling. Blood samples were drawn before surgery, after chest closure, as well as 24, 48, and 72 hours after surgery. Routine postoperative controls of creatine kinase and troponin T were performed at admission to the ICU, as well as 24, 48, and 72 hours after surgery.
HO-1 Protein and mRNA Levels in Heart Biopsies and PBMCs
HO-1 levels were analyzed in cardiac biopsies and PBMC. PBMCs were isolated from EDTA-blood with Ficoll-Plaque (Amersham Biosciences, United Kingdom) prefilled tubes (Leusosep, Greiner bioone, Austria). Cell pellets and biopsy samples for HO-1 mRNA analysis were immediately frozen in liquid nitrogen and stored at −80°C until analysis. Total RNA from PBMC cell pellets was isolated with the RNeasy mini kit according to manufacturer's protocol (Qiagen Sciences, MD). Cardiac biopsies were mixed with TRIzol reagent (Invitrogen) and homogenized using the Precellys CK14 Lysing Kit (Bertin Instruments) followed by extraction of total RNA according to the manufacturer's protocol (Invitrogen). Total RNA (1 μg) was reverse transcribed into cDNA by MMLV (Moloney murine leukemia virus) enzyme (Promega, Mannheim, Germany) with random hexamers (1 μg/μg total RNA). All polymerase chain reactions were performed using the SYBR Green kit (Bio-Rad, Hercules, CA). Primers for selected genes were designed using Primer3 software (http://frodo. wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) with the following sequences: HMOX1 (forward, 5'-AGACGGCTTCAAGCTGGTGA and reverse, 5'-TCTCCTTGTTGCGCTCAATCTC-3') and hRPLP0 (human ribosomal phosphoprotein P0; forward, 5'-GTCATCCAG CAGGTGTTCGAC-3' and reverse, 5'-CTCCAGGAAGCGAGAA TGCAG-3'). Quantitative polymerase chain reaction was performed as previously published using a CFX Real-Time PCR Detection Systems (Bio-Rad). 29 Quantitative polymerase chain reaction data were normalized to amounts of acidic ribosomal phosphoprotein P0. Primer sequences: data were analyzed according to the 2-ΔΔCT method. 30 For Western blot analysis, the dry cell pellets and tissues were lysed with a lysis buffer (RIPA [radioimmunoprecipitation assay buffer]-buffer) containing protease inhibitors. After centrifugation (14 000 rpm for 15 minutes at 4°C) the resulting supernatant was used to determine the protein concentration (BCA protein assay kit using a bovine serum albumin standard, Thermo Scientific). Western blotting was performed as previously described. 31 In brief, samples were heated at 98°C for 10 minutes and equal protein amounts were loaded onto an SDS-gel for protein separation. The gel was run at 120 V for 1.5 to 2 hours and then transferred to a Western blot membrane (20 V for 1.5 hours) using the dry blotting method. Ponceau staining was performed to verify protein loading. The membranes were blocked in 5 % milk for 1 hour and washed 3× for 5 minutes with Tris-buffered saline containing tween 20. The primary antibody used was anti-HO-1 (rabbit monoclonal antibody to HO-1; Abcam, Catalog No.: 52947), and the secondary antibody used was goat anti- overnight at 4°C, and incubation of secondary antibody was performed at room temperature for 1 hour. The membranes were incubated for 5 minutes in substrate solution and imaged using clear x-ray films (Thermo Scientific). The antibody staining and development procedure were repeated again using an anti-GAPDH antibody for normalization of the results. Using Image J (NIH) the amount of HO-1 protein (quantified as pixels under the curve) was evaluated and related to the expression of the housekeeping protein GAPDH (ratios are depicted).
Reactive Oxygen Species
The presence of reactive oxygen species (ROS) was determined in heart tissue lysates, as well as in patient serum. Measurements were performed using a Redoxsys systems (Ayutu Biosciences) system. Using this system, we were able to determine electrochemically the oxidation-reduction potential (mV), as well as the antioxidant capacity (µC) within the serum of patients. ROS levels in tissues were determined and calculated in relation to the corresponding protein concentrations.
Immunofluorescence-Based Staining of HO-1 Within the Appendage
Heart tissue paraffin sections (thickness of 5 µm) were subjected to standard deparaffinization techniques using a decreasing ethanol series followed by heat-mediated antigen retrieval (KOS Microwave Multifunctional Tissue Processor, Milestone Italy) in 10 mmol/L Citrate buffer (pH 6). After permeabilization of plasma membranes using 0.2% Triton X-100 in TBS (5 minutes), blocking of unspecific binding sites was performed using 1% bovine serum albumin and 10% goat serum in TBS for 60 minutes. Tissue sections were then incubated overnight at 4°C with the following primary antibody: rabbit polyclonal anti-HO-1 (Abcam ab13243, United Kingdom, 5 µg/mL). As an appropriate negative control for the HO-1 antibody, we used an isotype control (rabbit IgG polyclonal-Isotype control, Abcam, ab 27478; 5 µg/mL). Thereafter, heart tissue sections were incubated for 1 hour in the dark at room temperature with the appropriate secondary antibody (goat-anti-rabbit Alexa 546, A11035; Thermo Fischer, Austria; Major Resources Table in the online-only Data Supplement). After washing of the slides in TBS containing 0.1% Tween-20 (TBS-T), cell nuclei were stained with Hoechst (1 µg/mL) for 10 minutes. After 3 washing steps with TBS, slides were mounted in ProLong Gold antifade reagent (Thermo Fischer, Austria). Image acquisition was performed with a Nikon Eclipse Ti confocal laser microscope (Nikon, Austria).
Statistical Analysis
Main outcome parameters were HO-1 mRNA and protein induction and dose-response in the human heart and in PMBCs. Additional outcome parameters were the concentrations of ROS and postoperative creatine kinase and troponin T values. Major cardiac adverse events were assessed. A ratio of HO-1 protein level to GAPDH protein level was calculated to normalize results. A linear mixed model analysis was performed for repeated measurements after surgery to evaluate the effect of the study drug and the surgical procedure on outcome parameters. SPSS Statistics 24 (IBM Corp, Armonk, NY) was used to perform analysis. A P value of 0.05 or below was considered as statistically significant.
Results
Thirty-one patients were included into the study, and 27 study participants were randomized between March 2015 and June 2017. The trial was stopped after the interim analysis because of significant results. Surgeries of 3 patients had to be postponed after drug administration because of organizational reasons (n=2) or because of heparin-induced thrombocytopenia (n=1). These patients were, therefore, excluded from the study (Figure 1 ). Demographic data and procedural specifications are reported in postoperative bleeding because of an injury of the left mammary artery and 1 patient required a pacemaker implantation. Furthermore, one patient underwent reoperation because of a kinking of the right coronary artery after the initial Bentall procedure. No adverse drug reaction was observed after heme arginate infusion and no adverse events were related to the biopsy of the right ventricle. A strong, dose-dependent effect on HO-1 mRNA levels was observed in atrial tissue and in ventricular tissue before and after aortic cross-clamping (Table 2 , Graphical abstract). This transferred into a profound increase of HO-1 protein concentration and in the HO-1 protein ratio in atrial tissue. Ventricular protein concentration was not statistically different after heme arginate infusion. Both treatment doses as 1 group were also compared with placebo (12 344±6799 versus 6842±4343; P=0.082). The effect of HO-1 induction on protein levels vanished after reperfusion (Table 2) . A paired analysis irrespective of the study group showed a significantly higher mRNA level in atrial tissue compared with ventricular tissue (217.1±218.7 versus 100.8±124.8; P=0.018), but no acute effect of surgery could be detected when comparing biopsies before and after aortic cross-clamping (105.5±126.8 versus 120.2±139.2; P=0.584). Concordantly, no significant effect of aortic cross-clamping was observed on HO-1 protein levels (pre 10 980±6708 versus post 13 536±13 020; P=0.409).
Immunofluorescence-based detection of HO-1 protein expression within the patient's appendage revealed increased intracellular expression of HO-1 protein in cardiomyocytes of patients treated with heme arginate compared with the placebo group (Figure 2) . Moreover, images are suggesting a translocation of the HO-1 protein from a mainly cytoplasmatic distribution within the low-dose group to a nucleus near expression pattern, as well as also an enhanced nuclear expression pattern within the high-dose group.
PBMC HO-1 mRNA increased rapidly after cardiac surgery in the placebo group (49.7±34.6 before surgery compared with 125.9±156.5 at ICU arrival; P=0.023) and decreased continuously thereafter in a paired analysis. Heme arginate infusion 24 hours before surgery increased preoperative and perioperative PBMC mRNA concentrations (Figure 3 ). Surgery and heme arginate infusion were both significantly affecting HO-1 mRNA concentration (P<0.001 and 0.001 in the linear mixed models analysis). No significant effect on PBMC HO-1 protein levels could be detected (P=0.631 for surgery and P=0.112 for drug dose, respectively; Figure 3 ).
Carboxyhemoglobin was comparable between patients who received the study drug and control patients before surgery (1.5±0.3% versus 1.4±0.5%; P=0.634). HO-1 induction led to a significant increase of postoperative carboxyhemoglobin (1.7±0.3% versus 1.4±0.5%; P=0.041).
Plasma ROS levels were highly variable across patients and throughout the study period (Figure 4) . ROS static values and ROS capacity were significantly affected by surgery (P<0.001), but no effect of study drug administration was observed. Leukocytes, CRP (C-reactive protein), serum creatine kinase, and troponin T were significantly increased after surgery (P<0.001) but unchanged by heme arginate infusion.
Discussion
The induction of HO-1 before cardiac surgery and the experimental setting to detect mRNA and protein expression in cardiac tissue were safe and feasible. All patients survived until the last follow-up. Furthermore, procedural adverse events were not related to the study medication. Immunofluorescence-based detection of HO-1 (heme oxygenase-1) protein expression in the right atrial appendage. The images show the increased expression of HO-1 protein in patients treated with both doses of heme arginate (1 mg/kg, low dose and 3 mg/kg, high dose) compared with placebo. Images indicate a translocation of the HO-1 protein from a mainly cytoplasmatic distribution within the low-dose group to a nucleus near expression pattern, as well as an enhanced nuclear expression pattern within the high-dose group (marked with white arrows). As an appropriate negative control, we used the rabbit IgG isotype control antibody for HO-1.
As the main finding of this randomized, controlled clinical trial, HO-1 can be induced by heme arginate infusion 24 hours before cardiac surgery in cardiac tissue. Myocardial mRNA levels showed a strong, dose-dependent effect. This resulted in increased HO-1 protein concentration before aortic cross-clamping. Atrial samples were collected in addition to ventricular samples, as atrial metabolism might differ from ventricular tissue and protective effects may also be crucial in the atria (eg, to prevent postoperative atrial fibrillation). The effect was stronger in the atrium compared with the ventricle. Although the difference in ventricular protein levels was not statistically significant, this might also be because of difficult protein sampling in small biopsies compared with the larger atrial tissue samples. Furthermore, time to peak protein expression after heme arginate infusion may not be directly comparable to PBMC, which was previously described to peak at 24 hours. 25 Protein concentrations were not different after aortic cross-clamping, which may be because of the different processes happening during cardiac ischemia and intermittent cardioplegia with cold blood. Although HO-1 mRNA was induced by heme arginate infusion and surgery in PBMCs, no effect was seen on the HO-1 protein level in PBMCs. This may also be because of the limited time between induction and surgery, as well as the various effects of cardiac surgery, including the heart-lung machine on PBMCs thereafter, also including the usage and degradation of HO-1 protein. 25 Further, the mean age of the study population was 71 years, which differed significantly to our previous studies in healthy human subjects (mean age 27 years). 25 A slower protein expression may be present in the elderly patient population treated in this study.
Most importantly, postoperative but not preoperative carboxyhemoglobin was increased after HO-1 induction. This indicates functional HO-1 induction with relevant CO production during cellular stress induced by cardiac surgery but not under physiological preoperative conditions. CO was previously shown to protect cardiac tissue during IR injury. 23 We now provide evidence that HO-1 induction might also provide CO during on-pump cardiac surgery.
ROS were significantly affected by cardiac surgery. Static ROS increased continuously after surgery and ROS capacity decreased rapidly after surgery (Figure 4 ). The study drug had no influence on postoperative creatine kinase or troponin T values. Although this underlines the safety of the study drug, a protective effect cannot be excluded by this trial as the sample size was not calculated to demonstrate any effect on postoperative enzyme levels.
Although HO-1 induction in PBMCs was previously described in healthy human subjects, the induction of HO-1 in the human heart has not been described so far. 19, 25 Several in vitro and animal trials indicate a potential protective effect of HO-1 induction for several tissues, including the heart, but results are dependent on tissue expression, which may be different in humans compared with the animal model. 15, 32 The absence of HO-1, as analyzed in HO-1 knockout mice, leads to an increased susceptibility to IR injury. 33 We now provide evidence that HO-1 can be induced in cardiac tissue, which opens the area to clinical trials for the treatment of IR injury. The established mechanisms of HO-1 induction include direct reduction of the toxic heme molecule, which may be abundantly present during reperfusion after myocardial injury, including infarction. Furthermore, HO-1 protects potentially via effects mediated by carbon monoxide and biliverdin. 19 The proinflammatory state during reperfusion and the influx of leukocytes is ameliorated by HO-1 mediated effects. However, increased expression of HO-1 is not selective for a specific tissue or cell type and not compartmentalized. Thus, the net clinical effect of HO-1 activation in myocardial IR may be counteracted by enhanced inflammatory-mediated injury from effects of heme arginate on monocytes and macrophages with enhanced immunomodulatory actions. 35 The functional relevance of these opposing actions of pharmacological tissue HO-1 stimulation compared with that observed in macrophages has not been studied in cardiac patients and deserves attention in future clinical studies.
In addition to previous reports, we were able to confirm that a higher heme arginate dose led to increased nuclear expression pattern in vivo. Lin et al 36 previously reported a nuclear entrance of HO-1 in situations of oxidative stress or induction with heme. Nuclear HO-1 mediated the activation of oxidant-responsive transcriptions factors, which may provide an additional protection in the high-dose group. 36 The described pathways and mechanisms can potentially be used by pharmacological preconditioning with heme arginate before invasive procedures requiring periods of tissue ischemia. HO-1 induction may also be a valid option to enhance graft function and survival in cardiac transplantation. Recently, Thomas et al 37 were able to apply hemin preconditioning in patients undergoing renal transplantation, which led to an HO-1 induction in the donor, including invading macrophages. The clinical introduction of pharmacological preconditioning together with our results lay the ground for a clinical trial applying this approach in heart transplant donors to overcome limited ischemia time and early graft dysfunction. This and other potential clinical applications of HO-1 induction in cardiac surgery will be evaluated in the near future.
Limitations
Biopsy samples were small and protein concentration could not be measured in every sample. The sample size calculation was based on previous results but is small for a 3-arm randomized controlled trial. Additional surgical procedures might impact the postoperative course of cardiac enzymes and obscure a potential effect in this small group. This study was powered to identify protein expression in the heart but not to evaluate potential therapeutic effects.
Conclusions
HO-1 can be induced by heme arginate in the human heart. A higher dose leads to increased protein levels and enhanced nuclear expression pattern in cardiomyocytes. Protective effects of this therapeutic strategy should be evaluated in upcoming clinical trials. 
